Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1505-1509

  Yanada, Masamitsu ^a   Borthakur, Gautam ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   Pierce, Sherry ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Blood counts; Complete remission; Prognostication; Relapse free survival

Indexed keywords

CYTARABINE; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; COVARIANCE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 44749083077     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.002     Document Type: Article

References (17)

1. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
2. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
3. Keating M.J., Smith T.L., Gehan E.A., McCredie K.B., Bodey G.P., Spitzer G., et al. Factors related to length of complete remission in adult acute leukemia. Cancer 45 (1980) 2017-2029
4. Wheatley K., Burnett A.K., Goldstone A.H., Gray R.G., Hann I.M., Harrison C.J., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107 (1999) 69-79
5. Kern W., Haferlach T., Schoch C., Loffler H., Gassmann W., Heinecke A., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101 (2003) 64-70
6. Konopleva M., Cheng S.C., Cortes J.E., Hayes K.J., Pierce S.A., Andreeff M., et al. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica 88 (2003) 733-736
7. Marcucci G., Mrozek K., Ruppert A.S., Archer K.J., Pettenati M.J., Heerema N.A., et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol 22 (2004) 2410-2418
8. San Miguel J.F., Vidriales M.B., Lopez-Berges C., Diaz-Mediavilla J., Gutierrez N., Canizo C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98 (2001) 1746-1751
9. Kern W., Voskova D., Schoch C., Hiddemann W., Schnittger S., and Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104 (2004) 3078-3085
10. Krauter J., Gorlich K., Ottmann O., Lubbert M., Dohner H., Heit W., et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 21 (2003) 4413-4422
11. Gorello P., Cazzaniga G., Alberti F., Dell'Oro M.G., Gottardi E., Specchia G., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20 (2006) 1103-1108
12. Weisser M., Haferlach C., Hiddemann W., and Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia 21 (2007) 1177-1182
13. Estey E.H., Thall P.F., Cortes J.E., Giles F.J., O'Brien S., Pierce S.A., et al. Comparison of idarubicin+ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98 (2001) 3575-3583
14. Estey E.H., Shen Y., and Thall P.F. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95 (2000) 72-77
15. Beran M., Luthra R., Kantarjian H., and Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 28 (2004) 547-550
16. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 (2005) 254-266
17. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100 (2002) 2717-2723